Breakthrough infection elicits hypermutated IGHV3-53/3-66 public antibodies with broad and potent neutralizing activity against SARS-CoV-2 variants including the emerging EG.5 lineages
PLOS Pathogens · 2023
DOI: 10.1371/journal.ppat.1011856 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Pathogens, 2023. Verfasst von Ling Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Immunoengineering, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei…. Hauptthemen laut MEDLINE: COVID-19, Vaccines. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Technology of the People's Republic of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
The rapid emergence of SARS-CoV-2 variants of concern (VOCs) calls for efforts to study broadly neutralizing antibodies elicited by infection or vaccination so as to inform the development of vaccines and antibody therapeutics with broad protection. Here, we identified two convalescents of breakthrough infection with relatively high neutralizing titers against all tested viruses. Among 50 spike-specific monoclonal antibodies (mAbs) cloned from their B cells, the top 6 neutralizing mAbs (KXD01-06) belong to previously defined IGHV3-53/3-66 public antibodies. Although most antibodies in this class are dramatically escaped by VOCs, KXD01-06 all exhibit broad neutralizing capacity, particularly KXD01-03, which neutralize SARS-CoV-2 from prototype to the emerging EG.5.1 and FL.1.5.1. Deep mutational scanning reveals that KXD01-06 can be escaped by current and prospective variants with mutations on D420, Y421, L455, F456, N460, A475 and N487. Genetic and functional analysis further indicates that the extent of somatic hypermutation is critical for the breadth of KXD01-06 and other IGHV3-53/3-66 public antibodies. Overall, the prevalence of broadly neutralizing IGHV3-53/3-66 public antibodies in these two convalescents provides rationale for novel vaccines based on this class of antibodies. Meanwhile, KXD01-06 can be developed as candidates of therapeutics against SARS-CoV-2 through further affinity maturation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Laboratory of Immunoengineering, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, People's Republic of China.
- University of Science and Technology of China, Hefei, People's Republic of China.
ORCID-Profile: Teng Zuo
Förderung
- Ministry of Science and Technology of the People's Republic of China
- National Natural Science Foundation of China
Zitieren
APA
Li, L., Chen, X., Wang, Z., Li, Y., Wang, C., Jiang, L., & Zuo, T. (2023). Breakthrough infection elicits hypermutated IGHV3-53/3-66 public antibodies with broad and potent neutralizing activity against SARS-CoV-2 variants including the emerging EG.5 lineages. PLOS Pathogens. https://doi.org/10.1371/journal.ppat.1011856
Vancouver
Li L, Chen X, Wang Z, Li Y, Wang C, Jiang L, et al. Breakthrough infection elicits hypermutated IGHV3-53/3-66 public antibodies with broad and potent neutralizing activity against SARS-CoV-2 variants including the emerging EG.5 lineages. PLOS Pathogens. 2023. doi:10.1371/journal.ppat.1011856
BibTeX
@article{Li2023,
author = {Li, Ling and Chen, Xixian and Wang, Zuowei and Li, Yunjian and Wang, Chen and Jiang, Liwei and Zuo, Teng},
title = {Breakthrough infection elicits hypermutated IGHV3-53/3-66 public antibodies with broad and potent neutralizing activity against SARS-CoV-2 variants including the emerging EG.5 lineages},
journal = {PLOS Pathogens},
year = {2023},
doi = {10.1371/journal.ppat.1011856}
}
EUVIMED